During the last session, Milestone Pharmaceuticals Inc (NASDAQ:MIST)’s traded shares were 0.3 million, with the beta value of the company hitting 1.78. The 52-week high for the MIST share is $2.75, that puts it down -34.15 from that peak though still a striking 45.37% gain since the share price plummeted to a 52-week low of $1.12. The company’s market capitalization is $109.32M, and the average intraday trading volume over the past 10 days was 0.6 million shares, and the average trade volume was 534.26K shares over the past three months.
Milestone Pharmaceuticals Inc (MIST) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.40. MIST has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.
Milestone Pharmaceuticals Inc (NASDAQ:MIST) trade information
The stock’s 5-day price performance is 4.59%, and it has moved by 13.89% in 30 days. Based on these gigs, the overall price performance for the year is 33.12%. The short interest in Milestone Pharmaceuticals Inc (NASDAQ:MIST) is 0.45 million shares and it means that shorts have 2.46 day(s) to cover.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 79.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $10 respectively. As a result, MIST is trading at a discount of -387.8% off the target high and -387.8% off the low.
Milestone Pharmaceuticals Inc (MIST) estimates and forecasts
Statistics show that Milestone Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Milestone Pharmaceuticals Inc (MIST) shares have gone up 38.51% during the last six months, with a year-to-date growth rate more than the industry average at 55.40% against 16.50. In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -7.22%. While earnings are projected to return 54.82% in 2025.
MIST Dividends
Milestone Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Milestone Pharmaceuticals Inc (NASDAQ:MIST)’s Major holders
Milestone Pharmaceuticals Inc insiders own 0.69% of total outstanding shares while institutional holders control 57.01%, with the float percentage being 57.41%. BLACKROCK INC. is the largest shareholder of the company, while 46.0 institutions own stock in it. As of 2024-06-30, the company held over 4.97 million shares (or 9.9119% of all shares), a total value of $6.56 million in shares.
The next largest institutional holding, with 3.26 million shares, is of RTW INVESTMENTS, LP’s that is approximately 6.4921% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.3 million.
Also, the Mutual Funds coming in first place with the largest holdings of Milestone Pharmaceuticals Inc (MIST) shares are SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF and Fidelity NASDAQ Composite Index Fund . Data provided on Sep 30, 2024 indicates that SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF owns about 19.31 shares. This amounts to just over 0.04 percent of the company’s overall shares, with a $39587.0 market value. The same data shows that the other fund manager holds slightly less at 17.58, or about 0.03% of the stock, which is worth about $36030.0.
